A Study of the Safety and Efficacy of AGN-214868 in Patients With Postherpetic Neuralgia

Study Identifier
214868-002
CT.gov Identifier
NCT01129531
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Neuroscience - Other
    • Study Drug
  • AGN-214868
  • Placebo to AGN-214868
    • Phase
    Phase 2
    Sex
    Female & Male
    Age
    18 - 80 Years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Persistent postherpetic neuralgia (PHN) with nerve pain present for at least 9 months after onset of herpes zoster skin rash
    Exclusion Criteria:
    * Female patients with reproductive potential * Active herpes zoster skin rash * Current or anticipated treatment with acupuncture, TNS, or steroids * Current or anticipated use of topical analgesic agents with PHN * Treatment with botulinum toxin therapy of any serotype within the prior 12 weeks

    Protocol Summary

    This study will evaluate the safety and efficacy of AGN-214868 in patients with postherpetic neuralgia (PHN) - nerve pain.

    Study Locations

    Location
    Status
    Location
    Orlando, Florida, United States
    Status
    Not applicable
    Location
    Brno, Czech Republic
    Status
    Not applicable
    Location
    Kiel, Kiel, Germany
    Status
    Not applicable
    Location
    Katowice, Poland
    Status
    Not applicable